Trial Profile
A Phase I, Open-Label, Multicenter, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of HTI-1090 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs HTI 1090 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Atridia
- 07 Aug 2019 Status changed from active, no longer recruiting to completed.
- 19 Feb 2019 Planned End Date changed from 1 Apr 2019 to 1 Jul 2019.
- 28 Nov 2018 Planned End Date changed from 1 Mar 2019 to 1 Apr 2019.